Date: 2012-05-09
Type of information: Milestone
Compound: drug candidates against drug targets of interest to Boehringer Ingelheim
Company: Nuevolution (Denmark) Boehringer Ingelheim (Germany)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: * On September 20, 2011, Nuevolution has entered into collaboration with Boehringer Ingelheim, using Nuevolution’s proprietary Chemetics® drug discovery technology. Within the framework of the collaboration, hundreds of millions of diverse small molecules will be screened to discover and advance drug candidates against drug targets of interest to Boehringer Ingelheim. The Chemetics® platform uses innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale forming both small molecules and synthetic biologics. In its existing collaborations, Nuevolution has successfully addressed several challenging targets including protein-protein interactions by the identification of drug-like small molecules.
Financial terms: Under the terms of the agreement, Boehringer Ingelheim will provide Nuevo lution with an upfront payment, research funding, and milestone payments as candidate molecules progress through preclinical and clinical development and onto the market. In addition, Nuevo lution is eligible to receive royalties on the commercial sales of approved products. Further financial details were not disclosed.
Latest news: * On May 9, 2012, Nuevolution announced that it has received a milestone payment derived from its collaboration with Boehringer Ingelheim. The payment was triggered following identification of potent small molecule compounds that have been shown to disrupt the protein-protein interaction of an undisclosed therapeutic target. In its collaboration with Boehringer Ingelheim, Nuevolution has so far screened about 300 million small molecules against the first of the targets selected under the collaboration.
